|1||NCT02340221||Active, not recruiting||A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy||
||631||Female||18 Years and older (Adult, Older Adult)||NCT02340221||GO29058
|SANDPIPER||April 9, 2015||October 15, 2017||July 3, 2021||January 16, 2015||June 18, 2018||
|2||NCT02154490||Recruiting||Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer||
||Other / NIH||
||10000||All||18 Years and older (Adult, Older Adult)||NCT02154490||S1400
|June 16, 2014||April 1, 2022||April 1, 2022||June 3, 2014||August 31, 2018||
† Study has passed its completion date and status has not been verified in more than two years.